Analyst Price Target is $4.00
▲ +851.93% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Asensus Surgical in the last 3 months. The average price target is $4.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 851.93% upside from the last price of $0.42.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Asensus Surgical. This rating has held steady since April 2021, when it changed from a Hold consensus rating.
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.